Clinical Scorecard: Exploring the Intersection of Amyloid-Targeting Therapy and Antiplatelet Use in Alzheimer's Disease: A Clinical Dilemma?
At a Glance
Category
Detail
Condition
Key Mechanisms
Amyloid-targeting therapies (ATTs) and their association with amyloid-related imaging abnormalities (ARIAs), particularly ARIA-E and ARIA-H, in patients with concomitant antiplatelet therapy.
Target Population
Care Setting
Key Highlights
Exclude patients with severe bleeding disorders from ATT.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Increased risk of intracranial hemorrhage with concomitant antiplatelet and anticoagulant use.
Exclude patients with severe bleeding disorders from ATT.
Patient & Prescribing Data
Older adults with Alzheimer's disease and potential comorbidities.
Patients on SSRIs or NSAIDs may have heightened bleeding risks when treated with ATT.
